Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-7

what is weird to me is they only made $200k from the sales of FebriDx and ViraDx; there is no indication of what a full Q of sales will bring; and as I have said before, it is odd to me that revenue is so low from the non USA buyers

the wonderful news is the contract work is way up; we have a lot of mining services companies in Oz; can I call Lumos a pharma services company?

so with services way up, and product sales just getting started (manufacture and sell), and the odd one off motza of IP... yes, this fin year may be a bottom line of profit; that'll put the wind up the share price

the quarterly is very well written and presented... well done, management